2024-03-28T19:04:01Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1231182016-02-18T03:23:32Zcom_10261_134com_10261_1col_10261_387
Emerging therapeutic targets in regenerative medicine for the treatment of diabetes mellitus: A patent literature review
Álvarez Mercado, Anabel
Cobo-Vuilleumier, Nadia
Suárez Martín, Eduardo
Gauthier, Benoit R.
Junta de Andalucía
Fundación Progreso y Salud
Apoptosis
BACE-2
β -cells
Diabetes
GIP
Islet
LRH-1
Neurturin
Proliferation
GPR119
In recent years, the concept of preserving and/or replenishing the functional β-cell mass vital to sustain insulin output and normalized blood glucose levels has gained much interest as a therapeutic approach in regenerative medicine for the treatment of Diabetes Mellitus. Herein, we surveyed the diabetes area patent literature published in recent years to identify novel uprising therapeutic targets specifically implicated in regeneration and survival. One hundred and sixty nine international patent applications filed under the Patent Cooperation Treaty (PCT) (hereinafter, patents or applications) were highlighted from which 8 particular targets stood out with more than 4 patents published within the last few years. Not surprisingly, GLP-1 analogues and DPP-4 inhibitors along with GPR119 agonists and SGLT2 inhibitors were among the top ranked candidates. However, new emerging targets into the field of regenerative medicine for the treatment of diabetes include: 1) BACE-2; a protease that was recently shown to cleave the plasma membrane glycoprotein TMEM27 (also called collectrin) resulting in the inhibition of pancreatic β cell proliferation and insulin secretion, 2) GIP; a 42 amino acid incretin hormone that potentiates glucose induce insulin secretion and protect β-cells against cytokine-mediated apoptosis, 3) neurturin; a neurotrophic factor capable of improving blood glucose levels in high fat diet treated animals, and 4) LRH-1, an orphan nuclear receptor that improves islet viability. These novel targets along with GPR119 are further discussed in this review. © 2013 Bentham Science Publishers.
We would like to acknowledge Dr. L. St-Onge for his
fruitful discussions. Part of the work described herein was
funded by the Consejería de Salud, Junta de Andalucía (PI-
0727/ 2010 to B.R.G) and from the Fundación Publica Andaluza
Progreso y Salud
Peer Reviewed
2015-10-07T11:27:29Z
2015-10-07T11:27:29Z
2013
2015-10-07T11:27:29Z
artículo
http://purl.org/coar/resource_type/c_6501
doi: 10.2174/2210296511303010056
issn: 2210-2965
Recent Patents on Regenerative Medicine 3(1): 56- 62 (2013)
http://hdl.handle.net/10261/123118
10.2174/2210296511303010056
http://dx.doi.org/10.13039/501100011011
Postprint
http://dx.doi.org/10.2174/2210296511303010056
Sí
none
Bentham Science Publishers